The $50M initial tranche removes near-term cash runway risk and funds key catalysts (Phase 3 AURORA data, BLA filing). Watch for the second tranche milestones: positive AURORA data and a $125M financing. The conversion feature at $8.2526/share creates a potential overhang but is capped at $15M. The CMO departure is neutral given the deep bench. The stock should re-rate on de-risked funding and clear catalyst timelines.
Price Chart
Executive Summary
Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an initial $50 million tranche funded at closing. The non-dilutive financing extends cash runway into 2028 and funds clinical catalysts, including Phase 3 AURORA topline data in 1Q27. The CMO resigned for personal reasons, and the lender has the right to convert up to $15 million of principal into common stock at $8.2526 per share.
Key Financial Metrics
Key Facts
- Up to $150 million senior secured credit facility from K2 HealthVentures, with $50 million funded at closing on May 22, 2026.
- Second tranche of $25 million available Jan 1, 2027 – Dec 1, 2027, subject to positive Phase 3 AURORA data and raising $125M in financing (at least $75M equity).
- Third tranche of $25 million available Jan 1, 2028 – Jun 1, 2028, subject to FDA approval of Descartes-08 for gMG and first commercial sale.
- Fourth tranche of up to $50 million available at lender's sole discretion.
- Interest rate: greater of 8.95% or Prime + 2.20%, maturing June 1, 2030; amortization begins July 1, 2029.
- Lenders may convert up to $15 million of principal into common stock at $8.2526 per share (or lower in a qualified financing).
- Topline Phase 3 AURORA data for Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027.
- CMO Milos Miljkovic resigned effective May 31, 2026; Head of R&D Peter Traber to support ongoing trials and BLA preparation.
- Cash runway extended into 2028, covering three clinical data readouts and pre-commercial activities.
Financial Impact
Up to $150 million in new debt financing; $50 million drawn immediately. Interest at 8.95% floor. Potential dilution from conversion of up to $15 million principal into equity at $8.2526/share.
Risk Factors
- Phase 3 AURORA trial may fail to meet primary endpoint, jeopardizing second tranche and BLA timeline.
- Conversion of up to $15M principal into equity could dilute existing shareholders if stock trades below $8.2526.
- Stringent financial covenants (minimum cash, net product revenue of $40M/quarter from 2029) could trigger default if commercial launch is delayed.
- CMO departure may cause temporary disruption, though Head of R&D is experienced.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001453687-26-000087 |
| Document: pressrelease05262026.htm | 0001453687-26-000087 |
| Document: 0001453687-26-000087-index-headers.html | 0001453687-26-000087 |
| Document: 0001453687-26-000087-index.html | 0001453687-26-000087 |
| Document: 0001453687-26-000087.txt | 0001453687-26-000087 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $7.24 $7.21 | ▼ −0.41% | ▼ −0.21% | $6.28 (−13.26%) |
Aug 6, 2026 11w ago | 8-K | $8.76 $8.85 | ▲ +1.03% | ▲ +0.42% | $6.28 (−28.31%) |
May 26, 2026 21w ago | 8-K | $5.84 $5.86 | ▲ +0.34% | ▲ +0.12% | $6.28 (+7.53%) |
May 26, 2026 21w ago | Press Release | $6.45 $6.93 | ▲ +7.44% | ▲ +7.43% | $6.28 (−2.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers